Because of a lapse in government funding, the information on this website may not be up to date transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

NCI Dictionary of Cancer Terms

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Dictionary of Cancer Terms features 8,188 terms related to cancer and medicine.

We offer a widget that you can add to your website to let users look up cancer-related terms. Get NCI’s Dictionary of Cancer Terms Widget.

MET tyrosine kinase inhibitor PF-02341066
(… TY-ruh-seen KY-nays in-HIH-bih-ter …)
A drug used to treat non-small cell lung cancer that has spread to other parts of the body. It is used in patients whose cancer has a mutated (changed) form of the anaplastic lymphoma kinase (ALK) gene or the ROS1 gene. It is also being studied in the treatment of other types of cancer. MET tyrosine kinase inhibitor PF-02341066 blocks the proteins made by the mutated ALK and ROS1 genes. Blocking these proteins may stop the growth and spread of cancer cells. MET tyrosine kinase inhibitor PF-02341066 may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called crizotinib, PF-02341066, and Xalkori.